Publication
Eslicarbazepine acetate in post-stroke epilepsy: Clinical practice evidence from Euro-Esli
| dc.contributor.author | Sales, Francisco | |
| dc.contributor.author | Chaves, João | |
| dc.contributor.author | McMurray, Rob | |
| dc.contributor.author | Loureiro, Rui | |
| dc.contributor.author | Fernandes, Hélder | |
| dc.contributor.author | Villanueva, Vicente | |
| dc.date.accessioned | 2021-06-17T14:42:21Z | |
| dc.date.available | 2021-06-17T14:42:21Z | |
| dc.date.issued | 2020-12 | |
| dc.description.abstract | Objectives: To assess the effectiveness and safety/tolerability of eslicarbazepine acetate (ESL) in patients included in the Euro-Esli study who had focal seizures associated with post-stroke epilepsy (PSE). Materials and methods: Euro-Esli was a pooled analysis of 14 European clinical practice studies. Effectiveness assessments (evaluated after 3, 6 and 12 months of ESL treatment and at final follow-up ["last visit"]) included rates of response (≥50% seizure frequency reduction), seizure freedom (no seizures since at least the prior visit) and retention. Safety/tolerability was assessed throughout ESL treatment by evaluating adverse events (AEs) and discontinuation due to AEs. A post hoc analysis was conducted of patients with PSE versus patients without PSE ("non-PSE"). Results: Of 1656 patients included in the analysis, 76 (4.6%) had PSE and 1580 (95.4%) had non-PSE. Compared with non-PSE patients, PSE patients were significantly older, had significantly shorter epilepsy duration, significantly lower total baseline seizure frequency, and were treated with significantly fewer prior and concomitant antiepileptic drugs (P < .001 for all). At the last visit, the responder rate was significantly higher in PSE versus non-PSE patients (72.9% vs 60.6%; P = .040), as was the seizure freedom rate (48.6% vs 31.7%; P = .003). After 12 months, retention was significantly higher in PSE versus non-PSE patients (87.8% vs 77.4%; P = .035). The incidence of AEs was similar for PSE versus non-PSE patients (36.0% vs 35.8%; P = .966). Conclusions: These findings suggest that ESL may be an effective and well-tolerated treatment option for patients with focal seizures due to PSE. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Sales F, Chaves J, McMurray R, Loureiro R, Fernandes H, Villanueva V. Eslicarbazepine acetate in post-stroke epilepsy: Clinical practice evidence from Euro-Esli. Acta Neurol Scand. 2020 Dec;142(6):563-573. doi: 10.1111/ane.13323. Epub 2020 Aug 12. PMID: 32691850; PMCID: PMC7754143. | pt_PT |
| dc.identifier.doi | 10.1111/ane.13323 | pt_PT |
| dc.identifier.issn | 1600-0404 | |
| dc.identifier.uri | http://hdl.handle.net/10400.16/2476 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | Wiley-Blackwell | pt_PT |
| dc.relation.publisherversion | https://onlinelibrary.wiley.com/doi/epdf/10.1111/ane.13323 | pt_PT |
| dc.subject | Epilepsy | pt_PT |
| dc.subject | eslicarbazepine acetate | pt_PT |
| dc.subject | seizures | pt_PT |
| dc.subject | stroke | pt_PT |
| dc.title | Eslicarbazepine acetate in post-stroke epilepsy: Clinical practice evidence from Euro-Esli | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.conferencePlace | Denmark | pt_PT |
| oaire.citation.endPage | 573 | pt_PT |
| oaire.citation.issue | 6 | pt_PT |
| oaire.citation.startPage | 563 | pt_PT |
| oaire.citation.title | Acta neurologica Scandinavica | pt_PT |
| oaire.citation.volume | 142 | pt_PT |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |
Files
Original bundle
1 - 1 of 1